Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Benralizumab in DRESS Syndrome
NCT06734884Phase 2Not yet recruiting
- Sponsor
- CHU de Lille
- Start
- Jan 2027
- Primary completion
- Jan 2029
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in drug reaction with eosinophilia and systemic symptoms (DRESS) comparing Benralizumab with Placebo (2 arms). Primary endpoint: Total hospitalization duration for DRESS at 52 weeks. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
benralizumab
03
Conditions
drug reaction with eosinophilia and systemic symptoms (DRESS)
Beyond the preview
Go deeper on NCT06734884.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06734884.